Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD)

• Published in: Nutrients Vol. 11; no. 8; p. 1712
• Main Authors: Ji, Yun, Yin, Yue, Li, Ziru, Zhang, Weizhen
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.07.2019; MDPI
• Subjects: Animals; bacteria; Bacteria - genetics; Bacteria - metabolism; bile acids; bioactive compounds; carotenoids; Disease Progression; DNA; Fatty liver; Gastrointestinal Microbiome; glycolipids; Gut microbiota; hepatocytes; homeostasis; Host-Pathogen Interactions; Humans; indoles; ingredients; intestinal microorganisms; Intestines - microbiology; lipid metabolism; lipopolysaccharides; liver; Liver - metabolism; Liver - pathology; metabolites; Microbiota; Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - microbiology; peptidoglycans; phenolic compounds; portal vein; Review; short chain fatty acids; Signal Transduction; trimethylamine; metabolism; metabolite; liver disease; gut microbiota
• DOI: 10.3390/nu11081712
• ISSN: 2072-6643

Human gut microbiota has been increasingly recognized as a pivotal determinant of non-alcoholic fatty liver disease (NAFLD). Apart from the changes in the composition of gut microbiota, the components and metabolites derived from intestinal microbiota have emerged as key factors in modulating the pathological process of NAFLD. Compelling evidences have revealed that gut microbiota generates a variety of bioactive substances that interact with the host liver cells through the portal vein. These substances include the components derived from bacteria such as lipopolysaccharides, peptidoglycan, DNA, and extracellular vesicles, as well as the metabolites ranging from short-chain fatty acids, indole and its derivatives, trimethylamine, secondary bile acids, to carotenoids and phenolic compounds. The mechanisms underlying the hepatic responses to the bioactive substances from gut bacteria have been associated with the regulation of glycolipid metabolism, immune signaling response, and redox homeostasis. Illuminating the interplay between the unique factors produced from gut microbiome and the liver will provide a novel therapeutical target for NAFLD. The current review highlights the recent advances on the mechanisms by which the key ingredients and metabolites from gut microbiota modulate the development and progression of NAFLD.